Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Short term Debt: 2013-2024

Historic Short term Debt for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Dec 2024 value amounting to $234,000.

  • Amphastar Pharmaceuticals' Short term Debt rose 266.27% to $923,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $923,000, marking a year-over-year increase of 266.27%. This contributed to the annual value of $234,000 for FY2024, which is 46.33% down from last year.
  • As of FY2024, Amphastar Pharmaceuticals' Short term Debt stood at $234,000, which was down 46.33% from $436,000 recorded in FY2023.
  • Amphastar Pharmaceuticals' Short term Debt's 5-year high stood at $12.3 million during FY2020, with a 5-year trough of $234,000 in FY2024.
  • For the 3-year period, Amphastar Pharmaceuticals' Short term Debt averaged around $1.2 million, with its median value being $436,000 (2023).
  • As far as peak fluctuations go, Amphastar Pharmaceuticals' Short term Debt surged by 58.42% in 2020, and later tumbled by 85.69% in 2023.
  • Amphastar Pharmaceuticals' Short term Debt (Yearly) stood at $12.3 million in 2020, then slumped by 82.04% to $2.2 million in 2021, then spiked by 38.33% to $3.0 million in 2022, then tumbled by 85.69% to $436,000 in 2023, then plummeted by 46.33% to $234,000 in 2024.